Xtant Medical (NYSEAMERICAN:XTNT) Shares Cross Above 200 Day Moving Average – Should You Sell?

Xtant Medical Holdings, Inc. (NYSEAMERICAN:XTNT)’s share price passed above its two hundred day moving average during trading on Tuesday . The stock has a two hundred day moving average of $0.00 and traded as high as $0.67. Xtant Medical shares last traded at $0.61, with a volume of 25,953 shares changing hands.

Analyst Upgrades and Downgrades

Separately, Craig Hallum set a $1.50 price objective on Xtant Medical and gave the stock a “buy” rating in a report on Friday, October 18th.

Xtant Medical Price Performance

The company has a quick ratio of 0.88, a current ratio of 2.12 and a debt-to-equity ratio of 0.42. The company has a market cap of $84.80 million, a P/E ratio of -4.69 and a beta of 0.35.

Xtant Medical (NYSEAMERICAN:XTNT) last announced its earnings results on Tuesday, November 12th. The medical device company reported ($0.04) EPS for the quarter, missing the consensus estimate of ($0.02) by ($0.02). Xtant Medical had a negative return on equity of 37.07% and a negative net margin of 15.45%. The business had revenue of $27.94 million for the quarter.

Institutional Trading of Xtant Medical

A hedge fund recently bought a new stake in Xtant Medical stock. Evernest Financial Advisors LLC acquired a new position in shares of Xtant Medical Holdings, Inc. (NYSEAMERICAN:XTNT) during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 40,000 shares of the medical device company’s stock, valued at approximately $27,000. Hedge funds and other institutional investors own 69.33% of the company’s stock.

Xtant Medical Company Profile

Xtant Medical Holdings, Inc provides regenerative medicine products and medical devices for orthopedic and neurological surgeons. It offers OsteoSponge that provides a natural scaffold for cellular in-growth and exposes bone-forming proteins to the healing environment; OsteoSelect DBM Putty to mold into any shape and compressed into bony voids; OsteoSelect PLUS DBM Putty to deliver handling properties and ensure patient safety through validated terminal sterilization; 3Demin, a family of allografts that maximizes osteoconductivity and the osteoinductive potential of human bone; OsteoFactor, a processed allograft that contains retained growth factors found within the endosteum layer of allograft bone; OsteoVive Plus, a growth factor enriched cellular bone matrix; and nanOss family of products that provide osteoconductive nano-structured hydroxyapatite and an engineered extracellular matrix bioscaffold collagen carrier.